Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 13

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 13
---
 opportunities and collaboration agreements with leading academic institutions and other biotechnology 
 companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical    
 success, including programs beyond our target franchise areas and current technology footprint.                                             |

| ● | Invest                                                                                                                              
 in our HDAC platform technology and maximize its utility across cancer therapies. We are initially applying the platform to develop 
 drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the    
 data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform  
 technology, as well.                                                                                                                |
| ● | Enter                                                                                                                               
 into collaborations to realize the full potential of our platform. The breadth of our HDAC technology platform enables other        
 therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our    
 platform to maximize applications for cancer treatment.                                                                             |
| ● | Establish                                                                                                                           
 Shuttle Diagnostics, Inc. as a subsidiary of SHPH to advance development of the predictive biomarker (PC-RAD Test) and the PSMA     
 ligand (PSMA-B) to advance prostate cancer treatment.                                                                               |

Management Team

Our management team has significant experience in radiation oncology and in progressing products from early-stage research through clinical trials. Our Chief Executive Officer, or CEO, Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior academic and management positions including serving as Department Chairman, Hospital Medical Director and Cancer Center Director at Georgetown University Medical Center. Prior to co-founding our Company, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became public as NeoPharm, Inc. (Nasdaq: NEOL). He has experience in providing care for patients undergoing treatment for cancers of the prostate, breast, brain, lung, sarcomas and GI systems. Dr. Dritschilo has directed basic science research supported by grants from the National Cancer Institute (“NCI”) and performed clinical trials using drugs and radiation therapy. In addition, Dr. Dritschilo served as the principal investigator of pharmaceutical industry sponsored clinical evaluations of human interferon alpha-2 (Bristol-Myers) with radiation therapy and antisense raf oligonucleotides, LErafAON (NeoPharm) with radiation therapy. He serves as a Radiation Biology and Radiation Oncology expert on committees of the NIH to